Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 5/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22286019 | 1.00 | MIF (0.43) | MIFPPARGPPARAFAAHCNR2 | |
| SCHEMBL27470902 | 0.90 | MIF (0.48) | MIFPPARGPPARAMEN1ALDH1A1 | |
| SCHEMBL27470903 | 0.90 | MIF (0.48) | MIFPPARGPPARAMEN1ALDH1A1 | |
| SCHEMBL6838827 | 0.85 | MIF (0.46) | MIFFAAHMEN1ALDH1A1MAPT | |
| SCHEMBL349916 | 0.85 | MIF (0.58) | MIFFAAH | |
| SCHEMBL2589303 | 0.85 | MIF (0.46) | MIFFAAHMEN1ALDH1A1MAPT | |
| SCHEMBL2589301 | 0.85 | MIF (0.46) | MIFFAAHMEN1ALDH1A1MAPT | |
| SCHEMBL349917 | 0.85 | MIF (0.58) | MIFFAAH | |
| SCHEMBL16362264 | 0.84 | MIF (0.40) | MIFFAAHCNR2LMNAEGFR | |
| SCHEMBL9284047 | 0.83 | MIF (0.53) | MIFMEN1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | disclosed |
| WO-2024008766-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-01-11 | — | — | WO | disclosed |
| US-20230406832-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-12-21 | — | — | US | disclosed |
| US-11603359-B2 | Benzothiadiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-03-14 | — | — | US | disclosed |
| EP-3921028-B1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2022-11-09 | — | — | EP | disclosed |
| CN-113677398-A | Benzothiadiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2021-11-19 | — | — | CN | disclosed |
| US-20210179572-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-17 | — | — | US | disclosed |
| US-10941127-B2 | Benzothiadiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2021-03-09 | — | — | US | disclosed |
| US-20200247769-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247769-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | MIF 3706/4885PPARG 335/4885PPARA 464/4885 |
| US-11603359-B2 | Benzothiadiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | MIF 3706/4885PPARG 335/4885PPARA 464/4885 |
| US-20210179572-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | MIF 3706/4885PPARG 335/4885PPARA 464/4885 |
| US-20230406832-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | MIF 3706/4885PPARG 335/4885PPARA 464/4885 |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | MIF 4512/4885PPARG 598/4885PPARA 523/4885 |
| US-10941127-B2 | Benzothiadiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | MIF 3706/4885PPARG 335/4885PPARA 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.